Armata (ARMP) Stock Surges 150% After Breakthrough Bacteriophage Trial Results
Armata’s stock performance this week has been nothing short of dramatic. Prior to Oct. 22, ARMP had been trading in the low-$3 range. Once the late-breaking IDWeek data was announced, the shares rocketed – briefly hitting an intraday high near $16 before settling at about $8.87finviz.cominvesting.com. For context, that $8.87 close is the stock’s highest level in years. By midday on Oct. 22, Investing.com already noted the stock was up ~95% on the dayinvesting.com. By market close, FinViz data confirmed a +155.76% one-day gainfinviz.com. The trial results are the catalyst. Armata’s AP-SA02 is a “phage cocktail” – a mix of viruses engineered to infect and kill Staph. aureus bacteria. The diSArm Phase 2a study was a randomized, double-blind test of IV AP-SA02 plus standard antibiotics in patients with serious S. aureus bloodstream infections. As reported in the company’s PR materials, the response rate at Day 12 was 88% for AP-SA02 patients vs. only 58% for controlsprnewswire.com. Even more impressive, none of the AP-SA02 patients relapsed or failed treatment through 4 weeks, while ~25% of placebo patients didprnewswire.com. Dr. Birx noted that “all subjects infected with MRSA and treated with AP-SA02… cleared their infection with no relapse”prnewswire.comprnewswire.com. The treatment was well-tolerated
